NAMS logo

NEWAMSTERDAM PHARMA CO NV

NAMSNASDAQ
πŸ† #1739 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track NAMS
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.34B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-50.6%
Declining
πŸ“ŠGross Margin
97.8%
High
πŸ’΅FCF Margin
-581.6%
Thin
βš–οΈP/S Ratio
90.2x
Expensive
Otter Score
40
Weak
No chart data available for NAMS.

Trading Snapshot

Day Range
β€”
52-Week Range
$17.90 – $42.21
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
119.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$23M
Last Q Revenue
$19M
P/E Ratio
-11.4
P/S Ratio
90.2x
EPS (TTM)
$-1.65
Dividend Yield
0.00%
Dilution (1yr)
+17.9%
NAMS logo

NEWAMSTERDAM PHARMA CO NV

NAMS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$23Mβ–Ό βˆ’50.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.7%β–Ό βˆ’0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$226Mβ–² +28.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$148Mβ–Ό βˆ’7.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
114.4Mβ–² +17.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$490Mβ–Ό βˆ’$281M YoY
StockOtter Β· stockotter.space

About NEWAMSTERDAM PHARMA CO NV

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
40/100
Analyst data unavailable.

Latest News & Updates

News unavailable.